BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,050 filers reported holding BAXTER INTL INC in Q4 2018. The put-call ratio across all filers is 0.81 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $37,674,768 | -26.1% | 1,126,301 | -5.6% | 0.03% | -20.0% |
| Q1 2024 | $50,986,726 | +9.6% | 1,192,951 | -0.8% | 0.04% | +2.9% |
| Q4 2023 | $46,504,462 | +2.3% | 1,202,909 | -0.1% | 0.03% | -8.1% |
| Q3 2023 | $45,438,469 | -18.2% | 1,203,987 | -1.2% | 0.04% | -14.0% |
| Q2 2023 | $55,541,604 | -3.0% | 1,219,087 | -13.7% | 0.04% | 0.0% |
| Q1 2023 | $57,267,637 | -21.0% | 1,411,924 | -0.7% | 0.04% | -24.6% |
| Q4 2022 | $72,482,602 | -9.8% | 1,422,064 | -4.7% | 0.06% | -13.6% |
| Q3 2022 | $80,334,000 | -16.7% | 1,491,537 | -0.6% | 0.07% | -10.8% |
| Q2 2022 | $96,414,000 | -16.9% | 1,501,069 | +0.3% | 0.07% | -3.9% |
| Q1 2022 | $116,022,000 | -6.9% | 1,496,291 | +3.0% | 0.08% | +1.3% |
| Q4 2021 | $124,651,000 | -12.0% | 1,452,127 | -17.5% | 0.08% | -13.6% |
| Q3 2021 | $141,630,000 | +0.1% | 1,760,905 | +0.2% | 0.09% | +4.8% |
| Q2 2021 | $141,494,000 | -2.3% | 1,757,685 | +2.4% | 0.08% | -6.7% |
| Q1 2021 | $144,769,000 | +2.8% | 1,716,492 | -2.2% | 0.09% | -1.1% |
| Q4 2020 | $140,785,000 | -12.5% | 1,754,553 | -12.3% | 0.09% | -15.7% |
| Q3 2020 | $160,964,000 | -14.6% | 2,001,545 | -8.6% | 0.11% | -18.8% |
| Q2 2020 | $188,456,000 | -14.2% | 2,188,799 | -19.1% | 0.13% | -29.6% |
| Q1 2020 | $219,585,000 | +34.4% | 2,704,581 | +38.4% | 0.19% | +47.7% |
| Q4 2019 | $163,355,000 | -5.2% | 1,953,536 | -0.8% | 0.13% | -14.7% |
| Q3 2019 | $172,319,000 | +6.3% | 1,970,030 | -0.4% | 0.15% | +3.4% |
| Q2 2019 | $162,069,000 | -3.7% | 1,978,862 | -4.4% | 0.14% | -7.1% |
| Q1 2019 | $168,312,000 | +20.4% | 2,070,003 | -3.4% | 0.16% | +4.0% |
| Q4 2018 | $139,768,000 | -2.5% | 2,143,353 | +15.2% | 0.15% | -2.6% |
| Q3 2018 | $143,413,000 | +8.2% | 1,860,327 | +3.6% | 0.15% | -0.6% |
| Q2 2018 | $132,598,000 | +28.3% | 1,795,744 | +13.0% | 0.16% | +16.5% |
| Q1 2018 | $103,380,000 | +0.9% | 1,589,488 | +0.3% | 0.13% | +0.8% |
| Q4 2017 | $102,461,000 | +6.8% | 1,585,109 | +3.6% | 0.13% | -2.2% |
| Q3 2017 | $95,979,000 | -6.8% | 1,529,551 | -10.1% | 0.14% | -10.6% |
| Q2 2017 | $102,952,000 | +18.4% | 1,700,560 | +1.5% | 0.15% | +12.7% |
| Q1 2017 | $86,927,000 | +15.0% | 1,676,179 | -1.7% | 0.13% | +8.9% |
| Q4 2016 | $75,589,000 | +6.8% | 1,704,765 | +14.6% | 0.12% | +6.0% |
| Q3 2016 | $70,781,000 | -0.9% | 1,487,002 | -5.9% | 0.12% | -5.7% |
| Q2 2016 | $71,446,000 | -3.4% | 1,579,969 | -12.3% | 0.12% | -4.7% |
| Q1 2016 | $73,976,000 | +15.6% | 1,800,782 | +7.1% | 0.13% | +13.2% |
| Q4 2015 | $63,988,000 | +26.9% | 1,681,679 | +9.5% | 0.11% | +16.3% |
| Q3 2015 | $50,437,000 | -51.0% | 1,535,359 | +4.3% | 0.10% | -47.0% |
| Q2 2015 | $102,897,000 | +6.3% | 1,471,425 | +4.1% | 0.18% | +5.7% |
| Q1 2015 | $96,841,000 | +1.9% | 1,413,738 | +10.1% | 0.18% | -4.9% |
| Q4 2014 | $95,050,000 | -7.4% | 1,284,106 | -10.3% | 0.18% | -10.7% |
| Q3 2014 | $102,688,000 | -0.5% | 1,430,795 | +0.3% | 0.21% | -2.8% |
| Q2 2014 | $103,186,000 | -5.7% | 1,427,198 | -4.1% | 0.21% | -7.8% |
| Q1 2014 | $109,475,000 | +3.9% | 1,487,837 | -2.2% | 0.23% | +5.0% |
| Q4 2013 | $105,381,000 | -2.6% | 1,521,743 | -7.6% | 0.22% | -6.4% |
| Q3 2013 | $108,232,000 | -5.3% | 1,647,623 | -0.2% | 0.23% | -9.7% |
| Q2 2013 | $114,308,000 | – | 1,650,175 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 53,850,000 | $2,054,378,000 | 20.84% |
| Smithwood Advisers, L.P. | 1,000,000 | $38,150,000 | 10.54% |
| SECTOR GAMMA AS | 937,600 | $35,769,000 | 9.19% |
| Smithwood Advisers, L.P. | 500,000 | $19,075,000 | 5.27% |
| Veritas Asset Management LLP | 10,592,749 | $404,113,000 | 5.07% |
| York Capital Management Global Advisors, LLC | 7,887,822 | $300,921,000 | 4.47% |
| Iguana Healthcare Management, LLC | 325,000 | $12,399,000 | 4.08% |
| Osher Van de Voorde Investment Management | 174,160 | $6,644,000 | 3.82% |
| PURA VIDA INVESTMENTS, LLC | 200,000 | $7,630,000 | 3.22% |
| Governors Lane LP | 600,000 | $22,890,000 | 3.22% |